Skip to main content
Erschienen in:

19.05.2024 | Research

Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT)

verfasst von: Yasamin Yousefi, Reza Nejati, Atiye Eslahi, Farzaneh Alizadeh, Shima Farrokhi, Ahmad Asoodeh, Majid Mojarrad

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Glioblastoma (GBM) stands out as the most prevalent and aggressive intracranial tumor, notorious for its poor prognosis. The current standard-of-care for GBM patients involves surgical resection followed by radiotherapy, combined with concurrent and adjuvant chemotherapy using Temozolomide (TMZ). The effectiveness of TMZ primarily relies on the activity of O6-methylguanine DNA methyltransferase (MGMT), which removes alkyl adducts from the O6 position of guanine at the DNA level, thereby counteracting the toxic effects of TMZ.

Method

In this study, we employed fusions of catalytically-inactive Cas9 (dCas9) to DNA methyltransferases (dCas9-DNMT3A) to selectively downregulation MGMT transcription by inducing methylation at MGMT promoter and K-M enhancer.

Result

Our findings demonstrate a significant reduction in MGMT expression, leading to intensified TMZ sensitivity in the HEK293T cell line.

Conclusion

This study serves as a proof of concept for the utilization of CRISPR-based gene suppression to overcome TMZ resistance and enhance the lethal effect of TMZ in glioblastoma tumor cells.
Literatur
1.
Zurück zum Zitat Hess KR, Broglio KR, Bondy ML (2004) Adult glioma incidence trends in the United States, 1977–2000. Cancer: Interdisciplinary Int J Am Cancer Soc 101(10):2293–2299CrossRef Hess KR, Broglio KR, Bondy ML (2004) Adult glioma incidence trends in the United States, 1977–2000. Cancer: Interdisciplinary Int J Am Cancer Soc 101(10):2293–2299CrossRef
2.
Zurück zum Zitat Ostrom QT et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neurooncology 16(suppl4):iv1–iv63 Ostrom QT et al (2014) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neurooncology 16(suppl4):iv1–iv63
5.
Zurück zum Zitat Kondo T (2022) Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin, genetic/epigenetic mutation and microenvironment. Seminars in Cancer Biology. Elsevier Kondo T (2022) Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin, genetic/epigenetic mutation and microenvironment. Seminars in Cancer Biology. Elsevier
6.
Zurück zum Zitat Rabah N, Ait Mohand F-E, Kravchenko-Balasha N (2023) Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery barriers. Int J Mol Sci 24(18):14256CrossRefPubMedPubMedCentral Rabah N, Ait Mohand F-E, Kravchenko-Balasha N (2023) Understanding Glioblastoma Signaling, Heterogeneity, Invasiveness, and Drug Delivery barriers. Int J Mol Sci 24(18):14256CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMed Stupp R et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMed
9.
Zurück zum Zitat Jovčevska I (2019) Genetic secrets of long-term glioblastoma survivors. Bosnian J Basic Med Sci 19(2):116 Jovčevska I (2019) Genetic secrets of long-term glioblastoma survivors. Bosnian J Basic Med Sci 19(2):116
10.
Zurück zum Zitat Kanzawa T et al (2003) Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99(6):1047–1052CrossRefPubMed Kanzawa T et al (2003) Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99(6):1047–1052CrossRefPubMed
12.
Zurück zum Zitat Yan Y et al (2016) Targeting autophagy to sensitive glioma to temozolomide treatment. J Experimental Clin cancer Res 35(1):23CrossRef Yan Y et al (2016) Targeting autophagy to sensitive glioma to temozolomide treatment. J Experimental Clin cancer Res 35(1):23CrossRef
13.
Zurück zum Zitat Nagel ZD et al (2017) DNA repair capacity in multiple pathways predicts chemoresistance in glioblastoma multiforme. Cancer Res 77(1):198–206CrossRefPubMed Nagel ZD et al (2017) DNA repair capacity in multiple pathways predicts chemoresistance in glioblastoma multiforme. Cancer Res 77(1):198–206CrossRefPubMed
14.
Zurück zum Zitat Hombach-Klonisch S et al (2018) Glioblastoma and chemoresistance to alkylating agents: involvement of apoptosis, autophagy, and unfolded protein response. Pharmacol Ther 184:13–41CrossRefPubMed Hombach-Klonisch S et al (2018) Glioblastoma and chemoresistance to alkylating agents: involvement of apoptosis, autophagy, and unfolded protein response. Pharmacol Ther 184:13–41CrossRefPubMed
15.
Zurück zum Zitat Everhard S et al (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neurooncology 11(4):348–356 Everhard S et al (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neurooncology 11(4):348–356
16.
Zurück zum Zitat Brandes AA et al (2017) Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma: clinical implications. Oncologist 22(4):432–437CrossRefPubMedPubMedCentral Brandes AA et al (2017) Role of MGMT methylation status at time of diagnosis and recurrence for patients with glioblastoma: clinical implications. Oncologist 22(4):432–437CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Binabaj MM et al (2018) The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol 233(1):378–386CrossRefPubMed Binabaj MM et al (2018) The prognostic value of MGMT promoter methylation in glioblastoma: a meta-analysis of clinical trials. J Cell Physiol 233(1):378–386CrossRefPubMed
18.
Zurück zum Zitat Dolan ME et al (1991) Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 51(13):3367–3372PubMed Dolan ME et al (1991) Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 51(13):3367–3372PubMed
19.
Zurück zum Zitat Quinn JA et al (2009) Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27(8):1262CrossRefPubMedPubMedCentral Quinn JA et al (2009) Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 27(8):1262CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Aasland D et al (2018) Repair gene O6-methylguanine‐DNA methyltransferase is controlled by SP1 and up‐regulated by glucocorticoids, but not by temozolomide and radiation. J Neurochem 144(2):139–151CrossRefPubMed Aasland D et al (2018) Repair gene O6-methylguanine‐DNA methyltransferase is controlled by SP1 and up‐regulated by glucocorticoids, but not by temozolomide and radiation. J Neurochem 144(2):139–151CrossRefPubMed
21.
Zurück zum Zitat Happold C et al (2018) Transcriptional control of O6-methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. J Neurochem 144(6):780–790CrossRefPubMed Happold C et al (2018) Transcriptional control of O6-methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma. J Neurochem 144(6):780–790CrossRefPubMed
22.
Zurück zum Zitat Wang K et al (2017) Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma. Cancer Cell Int 17(1):117CrossRefPubMedPubMedCentral Wang K et al (2017) Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma. Cancer Cell Int 17(1):117CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003CrossRefPubMed Hegi ME et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352(10):997–1003CrossRefPubMed
24.
Zurück zum Zitat Mansouri A et al (2018) MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neurooncology 21(2):167–178 Mansouri A et al (2018) MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges. Neurooncology 21(2):167–178
25.
Zurück zum Zitat Malley DS et al (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121(5):651–661CrossRefPubMed Malley DS et al (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121(5):651–661CrossRefPubMed
26.
Zurück zum Zitat Kitange GJ et al (2012) Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 18(15):4070–4079CrossRefPubMedPubMedCentral Kitange GJ et al (2012) Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res 18(15):4070–4079CrossRefPubMedPubMedCentral
27.
28.
Zurück zum Zitat Harris LC, Remack JS, Brent TP (1994) Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O 6-methylguanine DNA methyltransferease gene. Nucleic Acids Res 22(22):4614–4619CrossRefPubMedPubMedCentral Harris LC, Remack JS, Brent TP (1994) Identification of a 59 bp enhancer located at the first exon/intron boundary of the human O 6-methylguanine DNA methyltransferease gene. Nucleic Acids Res 22(22):4614–4619CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Yang J et al (2015) Clinical significance of epigenetic silencing and re–expression of O6–methylguanine–DNA methyltransferase using epigenetic agents in laryngeal carcinoma. Oncol Lett 9(1):35–42CrossRefPubMed Yang J et al (2015) Clinical significance of epigenetic silencing and re–expression of O6–methylguanine–DNA methyltransferase using epigenetic agents in laryngeal carcinoma. Oncol Lett 9(1):35–42CrossRefPubMed
30.
31.
Zurück zum Zitat Malley DS et al (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121:651–661CrossRefPubMed Malley DS et al (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121:651–661CrossRefPubMed
32.
Zurück zum Zitat Dahlrot RH et al (2018) Prognostic value of O-6‐methylguanine–DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. Neuropathology and applied neurobiology, 44(2): 172–184 Dahlrot RH et al (2018) Prognostic value of O-6‐methylguanine–DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. Neuropathology and applied neurobiology, 44(2): 172–184
33.
Zurück zum Zitat Brandner S et al (2021) MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Neurooncology 23(9):1457–1469 Brandner S et al (2021) MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Neurooncology 23(9):1457–1469
34.
Zurück zum Zitat Quillien V et al (2014) Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. J Neurooncol 116:487–496CrossRefPubMedPubMedCentral Quillien V et al (2014) Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. J Neurooncol 116:487–496CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Håvik AB et al (2012) MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Translational Med 10(1):1–13CrossRef Håvik AB et al (2012) MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Translational Med 10(1):1–13CrossRef
36.
Zurück zum Zitat Kreth S et al (2011) O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS ONE 6(2):e17156CrossRefPubMedPubMedCentral Kreth S et al (2011) O6-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation. PLoS ONE 6(2):e17156CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Mazor G et al (2019) The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death Dis 10(3):246CrossRefPubMedPubMedCentral Mazor G et al (2019) The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death Dis 10(3):246CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Yuan Y et al (2022) The E3 ubiquitin ligase HUWE1 acts through the N-Myc-DLL1-NOTCH1 signaling axis to suppress glioblastoma progression. Cancer Commun (Lond) 42(9):868–886CrossRefPubMed Yuan Y et al (2022) The E3 ubiquitin ligase HUWE1 acts through the N-Myc-DLL1-NOTCH1 signaling axis to suppress glioblastoma progression. Cancer Commun (Lond) 42(9):868–886CrossRefPubMed
Metadaten
Titel
Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O6-methylguanine DNA methyltransferase (MGMT)
verfasst von
Yasamin Yousefi
Reza Nejati
Atiye Eslahi
Farzaneh Alizadeh
Shima Farrokhi
Ahmad Asoodeh
Majid Mojarrad
Publikationsdatum
19.05.2024
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2024
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-024-04708-0

Kompaktes Leitlinien-Wissen Neurologie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Neurologie

Schlaganfall oder Schlaganfall-Imitator?

Ein breites Spektrum von Erkrankungen kann einen Schlaganfall vortäuschen. Bei der notwendigen schnellen Unterscheidung zwischen solchen „stroke mimics“ und echten Schlaganfällen können einige klinische Faktoren und Symptome unterstützend herangezogen werden. 

Ein pulverisierter Plastiklöffel im Gehirn

Das menschliche Gehirn besteht zu etwa 0,5% aus Nanoplastik – Tendenz weiter steigend. Nach Resultaten eine Autopsiestudie reichert sich Plastik im Gehirn 10- bis 30-fach stärker an als in anderen Organen – mit bislang noch völlig unklaren Folgen.

Schlaganfall durch wandernde A. carotis interna

Die Thrombolyse nützte nichts, vielmehr war eine Teilresektion des Zungenbeins nötig: Es hatte eine verlagerte Carotis interna komprimiert und so bei einem älteren Mann einen Schlaganfall ausgelöst. Per Bildgebung lässt sich eine solche Ursache manchmal nur schwer nachweisen.

Epileptischer Anfall nach Darmreinigung

Die Darmreinigung vor einer Koloskopie führte einen älteren Mann auf die Intensivstation: Seine Natriumwerte waren durch die Prozedur so gesunken, dass er Bewusstseinstrübungen und Krampfanfälle entwickelte.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.